Home・Aandelen Lijst・Cerus Corp

Cerus Corp

Gesloten

SectorGezondheidszorg

2.34 1.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.2

Max

2.35

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.3M -3M
Verkoop	-2.5M 57M
EPS	-0.01
Winstmarge	-5.191
Werknemers	261
EBITDA	-1.5M -712K

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+120.26% upside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-182M 433M
Vorige openingsprijs	1.04
Vorige sluitingsprijs	2.34

Nieuwssentiment

By Acuity

50%

156 / 340 Rangschikking in Healthcare

Cerus Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2026, 19:43 UTC

Cerus Corp shares are higher Wednesday, recovering from an earlier decline amid high trading volume. Broader market sentiment is influenced by ADP's employment report.

4 aug 2026, 19:11 UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

3 aug 2026, 19:56 UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

31 jul 2026, 23:06 UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

30 jul 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

29 jul 2026, 19:56 UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

28 jul 2026, 16:02 UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

27 jul 2026, 20:07 UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

24 jul 2026, 19:06 UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

23 jul 2026, 09:01 UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

22 jul 2026, 15:46 UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

21 jul 2026, 21:41 UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Peer Vergelijking

Prijswijziging

Cerus Corp Prognose

Koersdoel

By TipRanks

120.26% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD 120.26%

Hoogste 5 USD

Laagste 5 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cerus Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Cerus Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

156 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.